1. Home
  2. CC vs URGN Comparison

CC vs URGN Comparison

Compare CC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemours Company (The)

CC

Chemours Company (The)

N/A

Current Price

$12.67

Market Cap

2.1B

Sector

Industrials

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$24.93

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CC
URGN
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
CC
URGN
Price
$12.67
$24.93
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$16.20
★ $61.71
AVG Volume (30 Days)
★ 2.4M
1.1M
Earning Date
11-02-2026
11-04-2026
Dividend Yield
★ 2.75%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $6,638,000,000.00
$1,128,000.00
Revenue This Year
$2.02
$193.20
Revenue Next Year
$3.83
$64.97
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 7.36
N/A
52 Week Low
$10.44
$16.50
52 Week High
$28.67
$50.81

Technical Indicators

Market Signals
Indicator
CC
URGN
Relative Strength Index (RSI) 41.82 18.22
Support Level N/A $18.28
Resistance Level $16.26 $27.76
Average True Range (ATR) 0.64 2.03
MACD 0.05 -0.75
Stochastic Oscillator 18.75 3.48

Price Performance

Historical Comparison
CC
URGN

About CC Chemours Company (The)

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: